<DOC>
	<DOC>NCT01358825</DOC>
	<brief_summary>The aim of this study is to assess antibody persistence in infants who received three doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) or Infanrix-IPV/Hib™ (DTPa-IPV/Hib) at 3, 5 and 11 months of age in study NCT00307034.</brief_summary>
	<brief_title>Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Subjects who had received 3 doses of Infanrix hexa™ or InfanrixIPV/Hib™ in study NCT00307034. Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) LAR(s) can and will comply with the requirements of the protocol. A male or female subject aged 5 years at the time of study entry. Written informed consent obtained from the parent(s)/LAR(s) of the subject. Healthy subjects as established by medical history and clinical examination before entering into the study. Child in care. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a noninvestigational product. Use of any investigational or nonregistered product within 30 days prior to blood sampling. Evidence of previous or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis B, and Hib vaccination or disease since the study NCT00307034, with the exception of hepatitis B vaccination in the DTPaIPV/Hib group. Administration of immunoglobulins and/or any blood products within the 3 months prior to blood sampling. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. Family history of congenital or hereditary immunodeficiency.</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Infanrix-IPV/Hib</keyword>
	<keyword>Long-term follow up</keyword>
	<keyword>Persistence</keyword>
	<keyword>Infanrix hexa</keyword>
</DOC>